JP2011513294A - 人参抽出物による先天免疫応答および適応免疫応答の活性化 - Google Patents
人参抽出物による先天免疫応答および適応免疫応答の活性化 Download PDFInfo
- Publication number
- JP2011513294A JP2011513294A JP2010548206A JP2010548206A JP2011513294A JP 2011513294 A JP2011513294 A JP 2011513294A JP 2010548206 A JP2010548206 A JP 2010548206A JP 2010548206 A JP2010548206 A JP 2010548206A JP 2011513294 A JP2011513294 A JP 2011513294A
- Authority
- JP
- Japan
- Prior art keywords
- panax
- fraction
- cvt
- ginseng
- toll
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 230000033289 adaptive immune response Effects 0.000 title claims abstract description 23
- 230000034662 activation of innate immune response Effects 0.000 title 1
- 235000020710 ginseng extract Nutrition 0.000 title 1
- 235000003140 Panax quinquefolius Nutrition 0.000 claims abstract description 97
- 235000008434 ginseng Nutrition 0.000 claims abstract description 79
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 claims abstract description 70
- 230000015788 innate immune response Effects 0.000 claims abstract description 29
- 240000005373 Panax quinquefolius Species 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 23
- 235000013305 food Nutrition 0.000 claims abstract description 18
- 230000003213 activating effect Effects 0.000 claims abstract description 14
- 239000003814 drug Substances 0.000 claims abstract description 14
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 13
- 229940079593 drug Drugs 0.000 claims abstract description 10
- 240000004371 Panax ginseng Species 0.000 claims description 97
- 108020000411 Toll-like receptor Proteins 0.000 claims description 51
- 102000002689 Toll-like receptor Human genes 0.000 claims description 50
- 235000002789 Panax ginseng Nutrition 0.000 claims description 38
- 241000700605 Viruses Species 0.000 claims description 37
- 238000011282 treatment Methods 0.000 claims description 37
- 244000000626 Daucus carota Species 0.000 claims description 31
- 235000002767 Daucus carota Nutrition 0.000 claims description 31
- 208000006673 asthma Diseases 0.000 claims description 31
- 208000015181 infectious disease Diseases 0.000 claims description 29
- 230000009385 viral infection Effects 0.000 claims description 28
- 235000002791 Panax Nutrition 0.000 claims description 27
- 241000208343 Panax Species 0.000 claims description 27
- 210000004698 lymphocyte Anatomy 0.000 claims description 24
- 208000036142 Viral infection Diseases 0.000 claims description 23
- 206010020751 Hypersensitivity Diseases 0.000 claims description 18
- 230000004913 activation Effects 0.000 claims description 17
- 102000004127 Cytokines Human genes 0.000 claims description 16
- 108090000695 Cytokines Proteins 0.000 claims description 16
- 239000000203 mixture Substances 0.000 claims description 15
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 13
- 230000011664 signaling Effects 0.000 claims description 13
- 102100024333 Toll-like receptor 2 Human genes 0.000 claims description 12
- 208000026935 allergic disease Diseases 0.000 claims description 11
- 230000007815 allergy Effects 0.000 claims description 11
- 230000000840 anti-viral effect Effects 0.000 claims description 11
- 210000000612 antigen-presenting cell Anatomy 0.000 claims description 11
- 206010028980 Neoplasm Diseases 0.000 claims description 9
- 235000003174 Panax japonicus Nutrition 0.000 claims description 9
- 241000168720 Panax japonicus Species 0.000 claims description 9
- 235000003143 Panax notoginseng Nutrition 0.000 claims description 9
- 241000180649 Panax notoginseng Species 0.000 claims description 9
- 235000003181 Panax pseudoginseng Nutrition 0.000 claims description 9
- 241001527087 Panax vietnamensis Species 0.000 claims description 9
- 235000017726 Panax vietnamensis Nutrition 0.000 claims description 9
- 241000180664 Panax wangianus Species 0.000 claims description 9
- 235000003138 Panax wangianus Nutrition 0.000 claims description 9
- 201000011510 cancer Diseases 0.000 claims description 9
- 230000000813 microbial effect Effects 0.000 claims description 9
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 7
- 230000002458 infectious effect Effects 0.000 claims description 7
- 230000000241 respiratory effect Effects 0.000 claims description 7
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims description 6
- 108010060888 Toll-like receptor 2 Proteins 0.000 claims description 6
- 206010022000 influenza Diseases 0.000 claims description 6
- 230000002265 prevention Effects 0.000 claims description 6
- 241000725303 Human immunodeficiency virus Species 0.000 claims description 5
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims description 5
- 239000000833 heterodimer Substances 0.000 claims description 5
- 238000002360 preparation method Methods 0.000 claims description 5
- 230000028327 secretion Effects 0.000 claims description 5
- 241000711573 Coronaviridae Species 0.000 claims description 4
- XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 claims description 4
- 241000711931 Rhabdoviridae Species 0.000 claims description 4
- 230000003827 upregulation Effects 0.000 claims description 4
- 108010060804 Toll-Like Receptor 4 Proteins 0.000 claims description 2
- 108010060826 Toll-Like Receptor 6 Proteins 0.000 claims description 2
- 108010060889 Toll-like receptor 1 Proteins 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 abstract description 5
- 241000208340 Araliaceae Species 0.000 abstract 2
- 210000004027 cell Anatomy 0.000 description 51
- 210000004443 dendritic cell Anatomy 0.000 description 41
- 210000003979 eosinophil Anatomy 0.000 description 25
- 241000699670 Mus sp. Species 0.000 description 24
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 23
- 102000010168 Myeloid Differentiation Factor 88 Human genes 0.000 description 21
- 108010077432 Myeloid Differentiation Factor 88 Proteins 0.000 description 21
- 230000004044 response Effects 0.000 description 21
- 238000004519 manufacturing process Methods 0.000 description 20
- 102000004889 Interleukin-6 Human genes 0.000 description 17
- 108090001005 Interleukin-6 Proteins 0.000 description 17
- 238000000338 in vitro Methods 0.000 description 17
- 244000052769 pathogen Species 0.000 description 16
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 14
- 230000000694 effects Effects 0.000 description 14
- 239000002158 endotoxin Substances 0.000 description 14
- 229920006008 lipopolysaccharide Polymers 0.000 description 14
- 210000002540 macrophage Anatomy 0.000 description 14
- 102000007863 pattern recognition receptors Human genes 0.000 description 14
- 108010089193 pattern recognition receptors Proteins 0.000 description 14
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 13
- 210000001744 T-lymphocyte Anatomy 0.000 description 13
- 239000003446 ligand Substances 0.000 description 13
- 241000196324 Embryophyta Species 0.000 description 12
- 108010092408 Eosinophil Peroxidase Proteins 0.000 description 11
- 102000044708 Eosinophil peroxidases Human genes 0.000 description 11
- 101000831496 Homo sapiens Toll-like receptor 3 Proteins 0.000 description 11
- 102100024324 Toll-like receptor 3 Human genes 0.000 description 11
- 230000001965 increasing effect Effects 0.000 description 11
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 10
- 241000711975 Vesicular stomatitis virus Species 0.000 description 10
- 230000028993 immune response Effects 0.000 description 10
- 210000005007 innate immune system Anatomy 0.000 description 10
- 239000000047 product Substances 0.000 description 10
- 230000035755 proliferation Effects 0.000 description 10
- 230000029812 viral genome replication Effects 0.000 description 10
- 230000003612 virological effect Effects 0.000 description 10
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 9
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 9
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 9
- 239000000427 antigen Substances 0.000 description 9
- 108091007433 antigens Proteins 0.000 description 9
- 102000036639 antigens Human genes 0.000 description 9
- 230000014509 gene expression Effects 0.000 description 9
- 102000040650 (ribonucleotides)n+m Human genes 0.000 description 8
- 208000037883 airway inflammation Diseases 0.000 description 8
- 239000013566 allergen Substances 0.000 description 8
- 231100000673 dose–response relationship Toxicity 0.000 description 8
- 238000000684 flow cytometry Methods 0.000 description 8
- 230000000638 stimulation Effects 0.000 description 8
- 101000831567 Homo sapiens Toll-like receptor 2 Proteins 0.000 description 7
- 230000007123 defense Effects 0.000 description 7
- 239000000284 extract Substances 0.000 description 7
- 210000003630 histaminocyte Anatomy 0.000 description 7
- 230000021995 interleukin-8 production Effects 0.000 description 7
- 210000001616 monocyte Anatomy 0.000 description 7
- 230000001717 pathogenic effect Effects 0.000 description 7
- 210000003024 peritoneal macrophage Anatomy 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- 208000037874 Asthma exacerbation Diseases 0.000 description 6
- 102000019034 Chemokines Human genes 0.000 description 6
- 108010012236 Chemokines Proteins 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- 108090000467 Interferon-beta Proteins 0.000 description 6
- 102000000589 Interleukin-1 Human genes 0.000 description 6
- 108010002352 Interleukin-1 Proteins 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 108010057466 NF-kappa B Proteins 0.000 description 6
- 102000003945 NF-kappa B Human genes 0.000 description 6
- 210000003651 basophil Anatomy 0.000 description 6
- 230000001419 dependent effect Effects 0.000 description 6
- 238000011161 development Methods 0.000 description 6
- 239000013641 positive control Substances 0.000 description 6
- 210000002345 respiratory system Anatomy 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 229960005486 vaccine Drugs 0.000 description 6
- 241000282412 Homo Species 0.000 description 5
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 5
- 102100026720 Interferon beta Human genes 0.000 description 5
- 102000014150 Interferons Human genes 0.000 description 5
- 108010050904 Interferons Proteins 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 5
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 5
- 102100033117 Toll-like receptor 9 Human genes 0.000 description 5
- 210000003719 b-lymphocyte Anatomy 0.000 description 5
- 238000003501 co-culture Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 230000002327 eosinophilic effect Effects 0.000 description 5
- 210000004392 genitalia Anatomy 0.000 description 5
- 230000012010 growth Effects 0.000 description 5
- 230000003053 immunization Effects 0.000 description 5
- 238000002649 immunization Methods 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 230000003834 intracellular effect Effects 0.000 description 5
- 210000004072 lung Anatomy 0.000 description 5
- 230000035800 maturation Effects 0.000 description 5
- 230000000770 proinflammatory effect Effects 0.000 description 5
- 230000002829 reductive effect Effects 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- 239000012646 vaccine adjuvant Substances 0.000 description 5
- 229940124931 vaccine adjuvant Drugs 0.000 description 5
- 206010003645 Atopy Diseases 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 4
- 238000002965 ELISA Methods 0.000 description 4
- 101001057504 Homo sapiens Interferon-stimulated gene 20 kDa protein Proteins 0.000 description 4
- 101001055144 Homo sapiens Interleukin-2 receptor subunit alpha Proteins 0.000 description 4
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 102100027268 Interferon-stimulated gene 20 kDa protein Human genes 0.000 description 4
- 102000013462 Interleukin-12 Human genes 0.000 description 4
- 108010065805 Interleukin-12 Proteins 0.000 description 4
- 108010006444 Leucine-Rich Repeat Proteins Proteins 0.000 description 4
- 101100481579 Mus musculus Tlr11 gene Proteins 0.000 description 4
- 101100481580 Mus musculus Tlr12 gene Proteins 0.000 description 4
- 208000002606 Paramyxoviridae Infections Diseases 0.000 description 4
- 239000004480 active ingredient Substances 0.000 description 4
- 239000000556 agonist Substances 0.000 description 4
- 230000030741 antigen processing and presentation Effects 0.000 description 4
- 230000001580 bacterial effect Effects 0.000 description 4
- 230000009286 beneficial effect Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 238000009472 formulation Methods 0.000 description 4
- 230000006870 function Effects 0.000 description 4
- 230000002519 immonomodulatory effect Effects 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 230000008073 immune recognition Effects 0.000 description 4
- 229940027941 immunoglobulin g Drugs 0.000 description 4
- 229940047124 interferons Drugs 0.000 description 4
- 210000004901 leucine-rich repeat Anatomy 0.000 description 4
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 description 4
- 210000000822 natural killer cell Anatomy 0.000 description 4
- 230000000144 pharmacologic effect Effects 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 210000005000 reproductive tract Anatomy 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 208000012657 Atopic disease Diseases 0.000 description 3
- 206010010356 Congenital anomaly Diseases 0.000 description 3
- 241000255581 Drosophila <fruit fly, genus> Species 0.000 description 3
- 108010040721 Flagellin Proteins 0.000 description 3
- 102100039620 Granulocyte-macrophage colony-stimulating factor Human genes 0.000 description 3
- 101000946889 Homo sapiens Monocyte differentiation antigen CD14 Proteins 0.000 description 3
- 101000669460 Homo sapiens Toll-like receptor 5 Proteins 0.000 description 3
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 description 3
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 3
- -1 IL-1β Proteins 0.000 description 3
- 102000002227 Interferon Type I Human genes 0.000 description 3
- 108010014726 Interferon Type I Proteins 0.000 description 3
- 102000003814 Interleukin-10 Human genes 0.000 description 3
- 108090000174 Interleukin-10 Proteins 0.000 description 3
- 102000000588 Interleukin-2 Human genes 0.000 description 3
- 108010002350 Interleukin-2 Proteins 0.000 description 3
- 108010028921 Lipopeptides Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 102100035877 Monocyte differentiation antigen CD14 Human genes 0.000 description 3
- 208000037656 Respiratory Sounds Diseases 0.000 description 3
- 206010057190 Respiratory tract infections Diseases 0.000 description 3
- 102100039357 Toll-like receptor 5 Human genes 0.000 description 3
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 3
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 3
- 206010047924 Wheezing Diseases 0.000 description 3
- 230000004721 adaptive immunity Effects 0.000 description 3
- 239000002671 adjuvant Substances 0.000 description 3
- 239000000443 aerosol Substances 0.000 description 3
- 208000010668 atopic eczema Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 239000011230 binding agent Substances 0.000 description 3
- 230000037396 body weight Effects 0.000 description 3
- 230000004186 co-expression Effects 0.000 description 3
- 235000015872 dietary supplement Nutrition 0.000 description 3
- 238000001035 drying Methods 0.000 description 3
- 210000002919 epithelial cell Anatomy 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000003304 gavage Methods 0.000 description 3
- 230000009610 hypersensitivity Effects 0.000 description 3
- 230000007124 immune defense Effects 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000000411 inducer Substances 0.000 description 3
- 230000002757 inflammatory effect Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 238000002347 injection Methods 0.000 description 3
- 239000007924 injection Substances 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 210000000265 leukocyte Anatomy 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000007246 mechanism Effects 0.000 description 3
- 230000001404 mediated effect Effects 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 235000013336 milk Nutrition 0.000 description 3
- 239000008267 milk Substances 0.000 description 3
- 210000004080 milk Anatomy 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 210000000440 neutrophil Anatomy 0.000 description 3
- 102000039446 nucleic acids Human genes 0.000 description 3
- 108020004707 nucleic acids Proteins 0.000 description 3
- 150000007523 nucleic acids Chemical class 0.000 description 3
- 229940092253 ovalbumin Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 230000001960 triggered effect Effects 0.000 description 3
- 102100032814 ATP-dependent zinc metalloprotease YME1L1 Human genes 0.000 description 2
- 241000238876 Acari Species 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- 108010055166 Chemokine CCL5 Proteins 0.000 description 2
- 102000001327 Chemokine CCL5 Human genes 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241000255925 Diptera Species 0.000 description 2
- 241000709661 Enterovirus Species 0.000 description 2
- 206010014950 Eosinophilia Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- 108010017213 Granulocyte-Macrophage Colony-Stimulating Factor Proteins 0.000 description 2
- 108010043121 Green Fluorescent Proteins Proteins 0.000 description 2
- 102000004144 Green Fluorescent Proteins Human genes 0.000 description 2
- NYHBQMYGNKIUIF-UUOKFMHZSA-N Guanosine Chemical compound C1=NC=2C(=O)NC(N)=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O NYHBQMYGNKIUIF-UUOKFMHZSA-N 0.000 description 2
- 102000006354 HLA-DR Antigens Human genes 0.000 description 2
- 108010058597 HLA-DR Antigens Proteins 0.000 description 2
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical compound NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 2
- 101000763537 Homo sapiens Toll-like receptor 10 Proteins 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 102100022297 Integrin alpha-X Human genes 0.000 description 2
- 108010074328 Interferon-gamma Proteins 0.000 description 2
- 102000019223 Interleukin-1 receptor Human genes 0.000 description 2
- 108050006617 Interleukin-1 receptor Proteins 0.000 description 2
- 102000003812 Interleukin-15 Human genes 0.000 description 2
- 108090000172 Interleukin-15 Proteins 0.000 description 2
- 102000004388 Interleukin-4 Human genes 0.000 description 2
- 108090000978 Interleukin-4 Proteins 0.000 description 2
- 102000004890 Interleukin-8 Human genes 0.000 description 2
- 108090001007 Interleukin-8 Proteins 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 244000061176 Nicotiana tabacum Species 0.000 description 2
- 235000002637 Nicotiana tabacum Nutrition 0.000 description 2
- 108010058846 Ovalbumin Proteins 0.000 description 2
- 101800000795 Proadrenomedullin N-20 terminal peptide Proteins 0.000 description 2
- 108700008625 Reporter Genes Proteins 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 230000029662 T-helper 1 type immune response Effects 0.000 description 2
- 102100027009 Toll-like receptor 10 Human genes 0.000 description 2
- 206010046306 Upper respiratory tract infection Diseases 0.000 description 2
- DRTQHJPVMGBUCF-XVFCMESISA-N Uridine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-XVFCMESISA-N 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 239000000809 air pollutant Substances 0.000 description 2
- 231100001243 air pollutant Toxicity 0.000 description 2
- 201000009961 allergic asthma Diseases 0.000 description 2
- 230000000172 allergic effect Effects 0.000 description 2
- 208000030961 allergic reaction Diseases 0.000 description 2
- 229940037003 alum Drugs 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 235000008452 baby food Nutrition 0.000 description 2
- 239000002775 capsule Substances 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000004113 cell culture Methods 0.000 description 2
- 230000003915 cell function Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 230000016396 cytokine production Effects 0.000 description 2
- 230000001086 cytosolic effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000006866 deterioration Effects 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 210000001163 endosome Anatomy 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 208000024711 extrinsic asthma Diseases 0.000 description 2
- 239000007850 fluorescent dye Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000005090 green fluorescent protein Substances 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000010348 incorporation Methods 0.000 description 2
- 230000006698 induction Effects 0.000 description 2
- 239000012678 infectious agent Substances 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000977 initiatory effect Effects 0.000 description 2
- 230000017306 interleukin-6 production Effects 0.000 description 2
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 description 2
- 238000011813 knockout mouse model Methods 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 230000004199 lung function Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 210000003071 memory t lymphocyte Anatomy 0.000 description 2
- NZWOPGCLSHLLPA-UHFFFAOYSA-N methacholine Chemical compound C[N+](C)(C)CC(C)OC(C)=O NZWOPGCLSHLLPA-UHFFFAOYSA-N 0.000 description 2
- 229960002329 methacholine Drugs 0.000 description 2
- 244000000010 microbial pathogen Species 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 231100000252 nontoxic Toxicity 0.000 description 2
- 230000003000 nontoxic effect Effects 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 230000027758 ovulation cycle Effects 0.000 description 2
- 230000000242 pagocytic effect Effects 0.000 description 2
- 230000003071 parasitic effect Effects 0.000 description 2
- 239000002245 particle Substances 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 239000002304 perfume Substances 0.000 description 2
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 2
- 239000013612 plasmid Substances 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 230000001681 protective effect Effects 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 230000003362 replicative effect Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 208000023504 respiratory system disease Diseases 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 230000019491 signal transduction Effects 0.000 description 2
- 239000000779 smoke Substances 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- 239000000021 stimulant Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000004083 survival effect Effects 0.000 description 2
- 230000009885 systemic effect Effects 0.000 description 2
- 239000003826 tablet Substances 0.000 description 2
- 241000712461 unidentified influenza virus Species 0.000 description 2
- 210000001215 vagina Anatomy 0.000 description 2
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- 208000000884 Airway Obstruction Diseases 0.000 description 1
- 208000035285 Allergic Seasonal Rhinitis Diseases 0.000 description 1
- 108010083359 Antigen Receptors Proteins 0.000 description 1
- BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 241001674044 Blattodea Species 0.000 description 1
- 102100040840 C-type lectin domain family 7 member A Human genes 0.000 description 1
- 102000001902 CC Chemokines Human genes 0.000 description 1
- 108010040471 CC Chemokines Proteins 0.000 description 1
- 210000001239 CD8-positive, alpha-beta cytotoxic T lymphocyte Anatomy 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- MIKUYHXYGGJMLM-GIMIYPNGSA-N Crotonoside Natural products C1=NC2=C(N)NC(=O)N=C2N1[C@H]1O[C@@H](CO)[C@H](O)[C@@H]1O MIKUYHXYGGJMLM-GIMIYPNGSA-N 0.000 description 1
- NYHBQMYGNKIUIF-UHFFFAOYSA-N D-guanosine Natural products C1=2NC(N)=NC(=O)C=2N=CN1C1OC(CO)C(O)C1O NYHBQMYGNKIUIF-UHFFFAOYSA-N 0.000 description 1
- 102000010170 Death domains Human genes 0.000 description 1
- 108050001718 Death domains Proteins 0.000 description 1
- 102000000541 Defensins Human genes 0.000 description 1
- 108010002069 Defensins Proteins 0.000 description 1
- 201000004624 Dermatitis Diseases 0.000 description 1
- 208000000059 Dyspnea Diseases 0.000 description 1
- 206010013975 Dyspnoeas Diseases 0.000 description 1
- 241000792859 Enema Species 0.000 description 1
- 101710121417 Envelope glycoprotein Proteins 0.000 description 1
- 108700016651 Eosinophil Major Basic Proteins 0.000 description 1
- 102000056703 Eosinophil Major Basic Human genes 0.000 description 1
- 208000004262 Food Hypersensitivity Diseases 0.000 description 1
- 206010017533 Fungal infection Diseases 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 206010048461 Genital infection Diseases 0.000 description 1
- UFNDONGOJKNAES-UHFFFAOYSA-N Ginsenoside Rb1 Natural products CC(=CCCC(C)(OC1OC(COC2OC(CO)C(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CC(O)C45C)C UFNDONGOJKNAES-UHFFFAOYSA-N 0.000 description 1
- 235000010469 Glycine max Nutrition 0.000 description 1
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 1
- 241000238631 Hexapoda Species 0.000 description 1
- 101000746373 Homo sapiens Granulocyte-macrophage colony-stimulating factor Proteins 0.000 description 1
- 101000959820 Homo sapiens Interferon alpha-1/13 Proteins 0.000 description 1
- 101000595548 Homo sapiens TIR domain-containing adapter molecule 1 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- 241000257303 Hymenoptera Species 0.000 description 1
- 102100034349 Integrase Human genes 0.000 description 1
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 1
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 1
- 102100040019 Interferon alpha-1/13 Human genes 0.000 description 1
- 102100037850 Interferon gamma Human genes 0.000 description 1
- 102000003996 Interferon-beta Human genes 0.000 description 1
- 102000008070 Interferon-gamma Human genes 0.000 description 1
- 102000003816 Interleukin-13 Human genes 0.000 description 1
- 108090000176 Interleukin-13 Proteins 0.000 description 1
- 206010023644 Lacrimation increased Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 102000043136 MAP kinase family Human genes 0.000 description 1
- 108091054455 MAP kinase family Proteins 0.000 description 1
- 102000043131 MHC class II family Human genes 0.000 description 1
- 108091054438 MHC class II family Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000204031 Mycoplasma Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 206010073310 Occupational exposures Diseases 0.000 description 1
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 1
- 208000030852 Parasitic disease Diseases 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 241000224016 Plasmodium Species 0.000 description 1
- RJKFOVLPORLFTN-LEKSSAKUSA-N Progesterone Chemical class C1CC2=CC(=O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H](C(=O)C)[C@@]1(C)CC2 RJKFOVLPORLFTN-LEKSSAKUSA-N 0.000 description 1
- 208000003251 Pruritus Diseases 0.000 description 1
- 206010062106 Respiratory tract infection viral Diseases 0.000 description 1
- 206010061494 Rhinovirus infection Diseases 0.000 description 1
- 208000019802 Sexually transmitted disease Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 102100036073 TIR domain-containing adapter molecule 1 Human genes 0.000 description 1
- 102000003714 TNF receptor-associated factor 6 Human genes 0.000 description 1
- 108090000009 TNF receptor-associated factor 6 Proteins 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 241000223997 Toxoplasma gondii Species 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 108091023040 Transcription factor Proteins 0.000 description 1
- 102000040945 Transcription factor Human genes 0.000 description 1
- YURJSTAIMNSZAE-UHFFFAOYSA-N UNPD89172 Natural products C1CC(C2(CC(C3C(C)(C)C(O)CCC3(C)C2CC2O)OC3C(C(O)C(O)C(CO)O3)O)C)(C)C2C1C(C)(CCC=C(C)C)OC1OC(CO)C(O)C(O)C1O YURJSTAIMNSZAE-UHFFFAOYSA-N 0.000 description 1
- 208000024780 Urticaria Diseases 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046914 Vaginal infection Diseases 0.000 description 1
- 241000256856 Vespidae Species 0.000 description 1
- 229920000392 Zymosan Polymers 0.000 description 1
- 229960001138 acetylsalicylic acid Drugs 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 230000006978 adaptation Effects 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 210000005006 adaptive immune system Anatomy 0.000 description 1
- 102000035181 adaptor proteins Human genes 0.000 description 1
- 108091005764 adaptor proteins Proteins 0.000 description 1
- 230000002730 additional effect Effects 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 238000003915 air pollution Methods 0.000 description 1
- 210000005091 airway smooth muscle Anatomy 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 239000005557 antagonist Substances 0.000 description 1
- 230000036436 anti-hiv Effects 0.000 description 1
- 230000002924 anti-infective effect Effects 0.000 description 1
- 229940124350 antibacterial drug Drugs 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 239000002876 beta blocker Substances 0.000 description 1
- 229940097320 beta blocking agent Drugs 0.000 description 1
- DRTQHJPVMGBUCF-PSQAKQOGSA-N beta-L-uridine Natural products O[C@H]1[C@@H](O)[C@H](CO)O[C@@H]1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-PSQAKQOGSA-N 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000000560 biocompatible material Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000001574 biopsy Methods 0.000 description 1
- 210000001185 bone marrow Anatomy 0.000 description 1
- 235000012206 bottled water Nutrition 0.000 description 1
- 210000000621 bronchi Anatomy 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000013736 caramel Nutrition 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000007969 cellular immunity Effects 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000012512 characterization method Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229940044683 chemotherapy drug Drugs 0.000 description 1
- 229940126678 chinese medicines Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229940110456 cocoa butter Drugs 0.000 description 1
- 235000019868 cocoa butter Nutrition 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 108010025838 dectin 1 Proteins 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 230000012969 defense response to bacterium Effects 0.000 description 1
- 230000002939 deleterious effect Effects 0.000 description 1
- 239000002781 deodorant agent Substances 0.000 description 1
- 229940063223 depo-provera Drugs 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 230000008034 disappearance Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000000428 dust Substances 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000002996 emotional effect Effects 0.000 description 1
- 239000007920 enema Substances 0.000 description 1
- 229940079360 enema for constipation Drugs 0.000 description 1
- 235000015897 energy drink Nutrition 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 239000003256 environmental substance Substances 0.000 description 1
- 230000012173 estrus Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000005713 exacerbation Effects 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 210000003495 flagella Anatomy 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000020932 food allergy Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 235000013350 formula milk Nutrition 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229940089161 ginsenoside Drugs 0.000 description 1
- 229930182494 ginsenoside Natural products 0.000 description 1
- GZYPWOGIYAIIPV-JBDTYSNRSA-N ginsenoside Rb1 Chemical compound C([C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)O[C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(CC[C@H]4C(C)(C)[C@@H](O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O[C@H]5[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O5)O)CC[C@]4(C)[C@H]3C[C@H]2O)C)(C)CC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GZYPWOGIYAIIPV-JBDTYSNRSA-N 0.000 description 1
- TXEWRVNOAJOINC-UHFFFAOYSA-N ginsenoside Rb2 Natural products CC(=CCCC(OC1OC(COC2OCC(O)C(O)C2O)C(O)C(O)C1O)C3CCC4(C)C3C(O)CC5C6(C)CCC(OC7OC(CO)C(O)C(O)C7OC8OC(CO)C(O)C(O)C8O)C(C)(C)C6CCC45C)C TXEWRVNOAJOINC-UHFFFAOYSA-N 0.000 description 1
- YURJSTAIMNSZAE-HHNZYBFYSA-N ginsenoside Rg1 Chemical compound O([C@@](C)(CCC=C(C)C)[C@@H]1[C@@H]2[C@@]([C@@]3(C[C@@H]([C@H]4C(C)(C)[C@@H](O)CC[C@]4(C)[C@H]3C[C@H]2O)O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)C)(C)CC1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YURJSTAIMNSZAE-HHNZYBFYSA-N 0.000 description 1
- CBEHEBUBNAGGKC-UHFFFAOYSA-N ginsenoside Rg1 Natural products CC(=CCCC(C)(OC1OC(CO)C(O)C(O)C1O)C2CCC3(C)C2C(O)CC4C5(C)CCC(O)C(C)(C)C5CC(OC6OC(CO)C(O)C(O)C6O)C34C)C CBEHEBUBNAGGKC-UHFFFAOYSA-N 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 229940029575 guanosine Drugs 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000003862 health status Effects 0.000 description 1
- 108010080417 hemozoin Proteins 0.000 description 1
- 229960002897 heparin Drugs 0.000 description 1
- 229920000669 heparin Polymers 0.000 description 1
- 229960001340 histamine Drugs 0.000 description 1
- 230000003054 hormonal effect Effects 0.000 description 1
- 102000045718 human TLR2 Human genes 0.000 description 1
- 230000004727 humoral immunity Effects 0.000 description 1
- 229960002751 imiquimod Drugs 0.000 description 1
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 description 1
- 230000005934 immune activation Effects 0.000 description 1
- 230000006054 immunological memory Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 230000004957 immunoregulator effect Effects 0.000 description 1
- 238000010874 in vitro model Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000018041 innate immune response in mucosa Effects 0.000 description 1
- 229940079322 interferon Drugs 0.000 description 1
- 229960003130 interferon gamma Drugs 0.000 description 1
- 229960001388 interferon-beta Drugs 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 239000007928 intraperitoneal injection Substances 0.000 description 1
- 239000002085 irritant Substances 0.000 description 1
- 231100000021 irritant Toxicity 0.000 description 1
- 235000015094 jam Nutrition 0.000 description 1
- 230000004317 lacrimation Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 150000002617 leukotrienes Chemical class 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 235000021056 liquid food Nutrition 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000006210 lotion Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- PSGAAPLEWMOORI-PEINSRQWSA-N medroxyprogesterone acetate Chemical compound C([C@@]12C)CC(=O)C=C1[C@@H](C)C[C@@H]1[C@@H]2CC[C@]2(C)[C@@](OC(C)=O)(C(C)=O)CC[C@H]21 PSGAAPLEWMOORI-PEINSRQWSA-N 0.000 description 1
- 108020004999 messenger RNA Proteins 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- 210000005087 mononuclear cell Anatomy 0.000 description 1
- 239000002324 mouth wash Substances 0.000 description 1
- 229940051866 mouthwash Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 210000000107 myocyte Anatomy 0.000 description 1
- 210000003928 nasal cavity Anatomy 0.000 description 1
- 239000007922 nasal spray Substances 0.000 description 1
- 239000006218 nasal suppository Substances 0.000 description 1
- 201000009240 nasopharyngitis Diseases 0.000 description 1
- 239000006199 nebulizer Substances 0.000 description 1
- 239000013642 negative control Substances 0.000 description 1
- 230000003767 neural control Effects 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
- 235000021590 normal diet Nutrition 0.000 description 1
- 210000001331 nose Anatomy 0.000 description 1
- 239000002417 nutraceutical Substances 0.000 description 1
- 235000021436 nutraceutical agent Nutrition 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 231100000675 occupational exposure Toxicity 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229940046166 oligodeoxynucleotide Drugs 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 238000000643 oven drying Methods 0.000 description 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 1
- 230000000803 paradoxical effect Effects 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 230000036281 parasite infection Effects 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 210000005259 peripheral blood Anatomy 0.000 description 1
- 239000011886 peripheral blood Substances 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 239000000902 placebo Substances 0.000 description 1
- 229940068196 placebo Drugs 0.000 description 1
- 208000015768 polyposis Diseases 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 239000000955 prescription drug Substances 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000007112 pro inflammatory response Effects 0.000 description 1
- 239000000583 progesterone congener Substances 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000009696 proliferative response Effects 0.000 description 1
- 239000003380 propellant Substances 0.000 description 1
- 150000003180 prostaglandins Chemical class 0.000 description 1
- 235000004252 protein component Nutrition 0.000 description 1
- 235000011962 puddings Nutrition 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000007115 recruitment Effects 0.000 description 1
- 230000010076 replication Effects 0.000 description 1
- BXNMTOQRYBFHNZ-UHFFFAOYSA-N resiquimod Chemical compound C1=CC=CC2=C(N(C(COCC)=N3)CC(C)(C)O)C3=C(N)N=C21 BXNMTOQRYBFHNZ-UHFFFAOYSA-N 0.000 description 1
- 208000020029 respiratory tract infectious disease Diseases 0.000 description 1
- 230000008593 response to virus Effects 0.000 description 1
- 206010039083 rhinitis Diseases 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 102000035025 signaling receptors Human genes 0.000 description 1
- 108091005475 signaling receptors Proteins 0.000 description 1
- 201000009890 sinusitis Diseases 0.000 description 1
- 210000003491 skin Anatomy 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 206010041232 sneezing Diseases 0.000 description 1
- 235000014214 soft drink Nutrition 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 235000021055 solid food Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 238000001694 spray drying Methods 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 238000010025 steaming Methods 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 230000004960 subcellular localization Effects 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 239000002511 suppository base Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 230000008719 thickening Effects 0.000 description 1
- 229940104230 thymidine Drugs 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000003104 tissue culture media Substances 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- 102000027257 transmembrane receptors Human genes 0.000 description 1
- 108091008578 transmembrane receptors Proteins 0.000 description 1
- DRTQHJPVMGBUCF-UHFFFAOYSA-N uracil arabinoside Natural products OC1C(O)C(CO)OC1N1C(=O)NC(=O)C=C1 DRTQHJPVMGBUCF-UHFFFAOYSA-N 0.000 description 1
- 229940045145 uridine Drugs 0.000 description 1
- 239000013598 vector Substances 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
- 239000002435 venom Substances 0.000 description 1
- 210000001048 venom Anatomy 0.000 description 1
- 231100000611 venom Toxicity 0.000 description 1
- 230000007502 viral entry Effects 0.000 description 1
- 210000000605 viral structure Anatomy 0.000 description 1
- 210000005253 yeast cell Anatomy 0.000 description 1
- 235000013618 yogurt Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
- A61K36/258—Panax (ginseng)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/25—Araliaceae (Ginseng family), e.g. ivy, aralia, schefflera or tetrapanax
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Biotechnology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Botany (AREA)
- Medical Informatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
種々の用量のCVT−E002がin vitroでマウス単球性細胞のウイルス複製を阻害する能力を調査した。種々の用量(0、10、100、および500μg/ml)のCVT−E002およびHT−1001(ジンセノサイドRb1およびRg1を含み、米国特許第6,083,932号に記載の例示的人参画分)をコントロールとして(250〜2000μg)PBS緩衝液に溶解し、完全組織培養培地で最終濃度に希釈し、37℃でin vitroにてRAW−264マウスマクロファージ細胞に添加した。24または48時間の細胞処理後、処理または非処理の細胞培養物を単純ヘルペスウイルス2型(HSV−2)または水疱性口内炎ウイルス(VSV)に曝露した。プラークアッセイを使用して、ウイルス複製を評価した。CVT−E002およびコントロール培養物の上清を処理後の種々の時点で回収し、ELISAを使用してI型IFN、TNFα、IL−6、および一酸化窒素(NO)について評価した。用量依存様式でのCVT−E002処理後のRAW細胞によって、IL−6(図8A)、IFNβ(図8B)、およびNO(図9)のレベルが有意に上昇した。非処理培養物およびコントロール処理培養物は陰性であった。サイトカイン産生およびウイルス力価に関するデータを相関について試験した。
樹状細胞(DC)をリンパ球と共培養し、フローサイトメトリーを使用してリンパ球を特徴づけた。LPS刺激を、ポジティブコントロールとして使用した。RSVおよびPIVは、樹状細胞(DC)の存在下でCD3+CD4+CD25+T細胞の増殖を誘導することが見出された(図4、それぞれn=3)。リンパ球と培養した非感染DCと比較して、RSVはインターフェロンαおよびγ、TNFα、RANTES、IL−1、2、4、10、12、13、および15の産生を誘導する(図5、n=1)。各非感染コントロール(1とする)と比較してデータを示す。T細胞のみを使用したCVT−E002により、IFNγおよびIL12の放出が誘導された。DCのみを使用したCVT−E002により、TNF、IFNγ、IL−1、10、12、および15の放出が誘導された。ウイルスを有する細胞培養物へのCVT−E002の添加により、サイトカイン/ケモカイン放出が大いに増加した。さらに、非感染細胞と比較して、CVT−E002はウイルスを含まないDCの存在下でリンパ球増殖を誘導することができた(図6)。
樹状細胞(DC)は、GM−CSFおよびIL−4での7日間の処理によって血中単球から誘導した。DCを、5mg/mlの自己消光DQ−オボアルブミン(DQ−OVA)およびCVT−E002の存在下または非存在下でインキュベートした。DQ−OVAは、オボアルブミンに付着した蛍光色素である。インタクトな分子としてはDQ−OVAの蛍光を消光するが、DCによる抗原提示によって分解された場合、蛍光色素を放出して発光する。
CVT−E002がTLRとの相互作用を介して先天性免疫応答を活性化するかどうかを決定するために、CVT−E002がNF−κBを活性化してMyD88を介してシグナル伝達する能力を試験した。腹腔マクロファージを、正常マウス(C57Bl/6野生型)およびMyD88を欠くマウス(すなわち、「MyD88−/−」と示したMyD88ノックアウトマウス)から単離した。培養プレートに付着させるためのin vitroでの24時間のインキュベーション後、マクロファージを洗浄し、種々の用量のCVT−E002またはHT−1001で処理し、さらに24時間インキュベートした。HT−1001をコントロールとして使用した。上清を回収し、ELISAを使用してIL−1、IL−6、IFNβ、およびNOの産生について評価した。CpG DNA(MyD88依存性)およびdsRNA(TLR3のMyD88非依存性リガンド)を、ポジティブコントロールおよびネガティブコントロールとしてそれぞれ含めた。さらに、レポーター遺伝子(LacZ)を駆動するNF−κBプロモーターを使用してプラスミドを構築した。このプラスミドでトランスフェクトした細胞を、種々の用量のCVT−E002で処理し、レポーター遺伝子産物の産生について評価した。
CVT−E002の受容体であり得るTLRを同定するために、個々のTLR受容体のみを発現するように細胞を構築した。これらの細胞を、至適用量のCVT−E002およびコントロールTLRリガンド/アゴニストを使用してin vitroで処理し、これらの細胞の上清を使用してIL−1、IL−6、TNFα、およびNOの産生を測定した。個々のTLRを発現する細胞が機能的であることを確実にするために、各TLRの既知のリガンド/アゴニストを使用したポジティブコントロールを含めた。結果は、CVT−E002がTLR4のみを介してシグナル伝達しないことを示す。24時間のCVT−E002処理により、hTLR2、hTLR1/2、hTLR2/6、およびhTLR4でトランスフェクトした293細胞中のIL−8産生が刺激された(Pam3CSK/LPSコントロール)(図14)。48時間のCVT−E002処理により、hTLR2、hTLR1/2、hTLR2/6、およびhTLR4でトランスフェクトした293細胞中のIL−8産生が刺激された(Pam3CSK/LPSコントロール)(図15)。hTLR4は、hTLR4のMDRおよびCD14との同時発現を示す。両方の期間において、全受容体についてIL−8産生の有意な増加が認められた。
CVT−E002またはコントロールを、その食事において経口的に、鼻腔内に、または膣内にマウスに送達した。その後にマウスの鼻腔内または膣内を種々の用量のHSV−2またはインターフェロン感受性水疱性口内炎ウイルス(VSV)で攻撃した。ウイルス感染からの防御を、ウイルス攻撃後の種々の時点(感染1〜3日後および6日後)での体重測定、全体的な病状のモニタリング、およびプラークアッセイを使用した肺、生殖器洗浄液、および組織中の攻撃ウイルス力価の測定によって評価した(図17Aおよび17B)。
OVAおよびCVT−E002+OVAマウスをOVAおよびミョウバンの腹腔内注射を使用して2回感作する一方で、コントロール動物には免疫化を行わなかった。最後の免疫化から7日後に、コントロール動物およびCVT−E002+OVAマウスに200mg/kgのCVT−E002化合物を経管栄養によって7日間連続して投与した。最終経管栄養の24時間後、全マウスの鼻腔内を50μgのOVAで2回攻撃し、第2の攻撃の24時間後にAHRおよび気道炎症について評価した。長時間の休止(enhanced pause)(Penh)を、全身プレチスモグラフィによって測定して、メタコリン攻撃に応答したAHRを決定した(n=3)。*OVAまたはコントロール群と比較してP<0.05(図16A)。気道炎症を、BAL液中の好酸球数によって決定した(n=3)。*OVAまたはコントロール群と比較してP<0.05(図16B)。
Claims (32)
- 有効量の少なくとも1つの人参画分を被験体に投与する工程を含む、処置を必要とする被験体における先天免疫のシグナル伝達の活性化による予防、処置、または改善に感受性を示す状態を予防、処置、または改善する方法。
- 前記状態が、アレルギー、喘息、ウイルス感染、微生物感染、および癌からなる群より選択される、請求項1に記載の方法。
- 前記ウイルス感染が、インフルエンザ、コロナウイルス、ヘルペス、呼吸器合胞体ウイルス、ラブドウイルス科、およびヒト免疫不全ウイルスを含む、呼吸器または粘膜伝染性ウイルスに由来する、請求項2に記載の方法。
- 前記画分が、Panax quinquefolius、Panax trifolia、Panax ginseng、Panax japonicus、Panax schinseng、Panax notoginseng、Panax pseudoginseng、Panax vietnamensis、Panax elegatior、Panax wangianus、Panax bipinratifidus、水参または生参、白参、および紅参からなる群より選択される人参から作製される、請求項2に記載の方法。
- 前記画分が、Panax quinquefoliusの画分である、請求項4に記載の方法。
- 前記画分が、CVT−E002、PQ2、PQ223、ならびにCVT−E002、PQ2、およびPQ223由来の精製画分からなる群より選択される、請求項5に記載の方法。
- 前記画分が、CVT−E002である、請求項6に記載の方法。
- CVT−E002が、Toll様受容体由来のシグナル伝達を調整する、請求項7に記載の方法。
- 前記Toll様受容体が、Toll様受容体2である、請求項8に記載の方法。
- 前記Toll様受容体が、Toll様受容体2およびToll様受容体6のヘテロ二量体である、請求項8に記載の方法。
- 前記Toll様受容体が、Toll様受容体2およびToll様受容体1のヘテロ二量体である、請求項8に記載の方法。
- 前記Toll様受容体が、Toll様受容体4である、請求項8に記載の方法。
- CVT−E002が、リンパ球および抗原提示細胞の上方制御、サイトカイン分泌、抗ウイルス因子の分泌、またはその組み合わせを誘導する、請求項7に記載の方法。
- 状態を予防、処置、または改善するために先天免疫応答および適応免疫応答を活性化するための人参画分。
- 前記画分が、Panax quinquefolius、Panax trifolia、Panax ginseng、Panax japonicus、Panax schinseng、Panax notoginseng、Panax pseudoginseng、Panax vietnamensis、Panax elegatior、Panax wangianus、Panax bipinratifidus、水参または生参、白参、および紅参からなる群より選択される人参から作製される、請求項14に記載の画分。
- 前記画分が、Panax quinquefoliusの画分である、請求項15に記載の画分。
- 前記画分が、CVT−E002、PQ2、PQ223、ならびにCVT−E002、PQ2、およびPQ223由来の精製画分からなる群より選択される、請求項16に記載の画分。
- 前記画分が、CVT−E002である、請求項17に記載の画分。
- 請求項14に記載の画分を、食品が含まれる、状態を予防、処置、または改善するために先天免疫応答および適応免疫応答を活性化するための別の薬物または1つまたは複数の薬学的に許容可能なキャリアと組み合わせて含む薬学的組成物。
- 前記画分が、Panax quinquefolius、Panax trifolia、Panax ginseng、Panax japonicus、Panax schinseng、Panax notoginseng、Panax pseudoginseng、Panax vietnamensis、Panax elegatior、Panax wangianus、Panax bipinratifidus、水参または生参、白参、および紅参からなる群より選択される人参から作製される、請求項19に記載の組成物。
- 前記画分が、Panax quinquefoliusの画分である、請求項20に記載の組成物。
- 前記画分が、CVT−E002、PQ2、PQ223、ならびにCVT−E002、PQ2、およびPQ223由来の精製画分からなる群より選択される、請求項21に記載の組成物。
- 前記画分が、CVT−E002である、請求項22に記載の組成物。
- 状態を予防、処置、または改善するために先天免疫応答および適応免疫応答を活性化するための薬学的組成物または食品の調製のための請求項14に記載の人参画分の使用。
- 前記状態が、アレルギー、喘息、ウイルス感染、微生物感染、および癌からなる群より選択される、請求項24に記載の使用。
- 前記ウイルス感染が、インフルエンザ、コロナウイルス、ヘルペス、呼吸器合胞体ウイルス、ラブドウイルス科、およびヒト免疫不全ウイルスを含む、呼吸器または粘膜伝染性ウイルスに由来する、請求項25に記載の使用。
- 前記画分が、Panax quinquefolius、Panax trifolia、Panax ginseng、Panax japonicus、Panax schinseng、Panax notoginseng、Panax pseudoginseng、Panax vietnamensis、Panax elegatior、Panax wangianus、Panax bipinratifidus、水参または生参、白参、および紅参からなる群より選択される人参から作製される、請求項25に記載の使用。
- 前記画分が、Panax quinquefoliusの画分である、請求項27に記載の使用。
- 前記画分が、CVT−E002、PQ2、PQ223、ならびにCVT−E002、PQ2、およびPQ223由来の精製画分からなる群より選択される、請求項28に記載の使用。
- 前記画分が、CVT−E002である、請求項29に記載の使用。
- 請求項14に記載の人参画分を被験体に投与する工程を含む、活性化を必要とする被験体における状態を予防、処置、または改善するために先天免疫応答および適応免疫応答を活性化するための方法。
- Toll様受容体由来のシグナル伝達の調整を含む先天免疫のシグナル伝達の活性化に関連する状態を予防、処置、または改善するための方法であって、かかる予防、処置、または改善を必要とする被験体への請求項14に記載の人参画分の投与による、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US6435408P | 2008-02-29 | 2008-02-29 | |
US61/064,354 | 2008-02-29 | ||
PCT/IB2009/000379 WO2009106975A2 (en) | 2008-02-29 | 2009-02-27 | Activation of innate and adaptive immune responses by a ginseng extract |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2011513294A true JP2011513294A (ja) | 2011-04-28 |
JP2011513294A5 JP2011513294A5 (ja) | 2012-01-12 |
JP5879037B2 JP5879037B2 (ja) | 2016-03-08 |
Family
ID=41016524
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2010548206A Active JP5879037B2 (ja) | 2008-02-29 | 2009-02-27 | 人参抽出物による先天免疫応答および適応免疫応答の活性化 |
Country Status (15)
Country | Link |
---|---|
US (2) | US20110086052A1 (ja) |
EP (1) | EP2268295B1 (ja) |
JP (1) | JP5879037B2 (ja) |
KR (1) | KR101664871B1 (ja) |
CN (1) | CN102014941B (ja) |
AU (1) | AU2009219793B2 (ja) |
BR (1) | BRPI0908541B8 (ja) |
CA (1) | CA2716366C (ja) |
ES (1) | ES2539532T3 (ja) |
MX (1) | MX2010009479A (ja) |
MY (1) | MY158195A (ja) |
NZ (1) | NZ587615A (ja) |
PL (1) | PL2268295T3 (ja) |
SG (1) | SG188833A1 (ja) |
WO (1) | WO2009106975A2 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210196776A1 (en) * | 2018-05-02 | 2021-07-01 | Amorepacific Corporation | Composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103622982A (zh) * | 2013-10-24 | 2014-03-12 | 浙江大学 | 人参皂甙Rg1在制备抗内毒素作用于Toll样受体4药物上的应用 |
KR101677855B1 (ko) * | 2014-08-08 | 2016-11-21 | 중앙대학교 산학협력단 | 자일리톨을 유효성분으로 함유하는 호흡기 세포융합 바이러스 감염증 예방 또는 치료용 조성물 |
KR101944953B1 (ko) | 2016-07-29 | 2019-02-01 | 메타볼랩(주) | 점막용 항인플루엔자 바이러스 조성물 |
KR101837691B1 (ko) * | 2016-08-12 | 2018-03-14 | 한국한의학연구원 | 삼칠근 추출물을 함유하는 항바이러스용 조성물 |
KR101940042B1 (ko) | 2017-05-11 | 2019-01-21 | 주식회사 케이티앤지 | 곰보배추 및 홍삼으로 구성된 조합 추출물을 유효성분으로 함유하는 호흡기염증 질환의 예방 및 치료용 조성물 |
WO2019212203A1 (ko) * | 2018-05-02 | 2019-11-07 | ㈜아모레퍼시픽 | 인삼열매 다당체를 포함하는 인플루엔자 바이러스 감염 예방 또는 억제용 조성물 |
AU2020280860B2 (en) * | 2019-05-20 | 2024-01-18 | Cj Cheiljedang Corporation | Anti-influenza virus composition, composition for treating respiratory diseases, and anti-aging composition, comprising dark ginseng extract |
MX2022011573A (es) * | 2020-03-20 | 2023-01-04 | Novel Concepts Medical Ltd | Composiciones y métodos para el tratamiento de tumores sólidos y blandos y enfermedades proliferativas. |
KR102326439B1 (ko) * | 2020-04-20 | 2021-11-16 | 주식회사 네이처센스 | 인삼을 포함하는 항균, 항염, 항바이러스 및 면역 기능 개선용 조성물 |
US20240091250A1 (en) * | 2020-12-15 | 2024-03-21 | Jacqueline J. Shan | American ginseng root fractions, processes of their preparation and uses thereof |
WO2023008981A1 (ko) * | 2021-07-30 | 2023-02-02 | 경희대학교 산학협력단 | 항바이러스 조성물 및 이의 이용 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002017299A (ja) * | 2000-07-10 | 2002-01-22 | Rasheru Seiyaku Kk | 健康食品 |
JP2002508329A (ja) * | 1997-12-12 | 2002-03-19 | シーヴイ テクノロジーズ インコーポレイテッド | 北アメリカ薬用人参分留物の形成方法、それらを含む生成物および免疫賦活剤としての使用方法 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6156A (en) | 1849-03-10 | Stove foe heating apartments | ||
EP0030444B1 (en) | 1979-12-03 | 1985-01-30 | Kitasato Kenkyusho | A process for preparing substances having interferon inducing activity |
JPS6118722A (ja) | 1984-07-05 | 1986-01-27 | Wakunaga Seiyaku Kk | 生体防御能亢進剤 |
SE452776B (sv) | 1986-04-02 | 1987-12-14 | Johansson Hanna Maria E | Forfarande for framstellning av oligosackarider |
JPH0643327B2 (ja) | 1987-03-27 | 1994-06-08 | 株式会社ツムラ | 免疫賦活剤 |
JPH0245499A (ja) | 1988-08-06 | 1990-02-15 | Wakunaga Pharmaceut Co Ltd | オタネニンジン糖タンパク質およびその用途 |
JPH0245501A (ja) | 1988-08-06 | 1990-02-15 | Wakunaga Pharmaceut Co Ltd | 竹節ニンジン多糖およびその用途 |
JPH05317041A (ja) | 1991-06-05 | 1993-12-03 | Nippon Oil Co Ltd | 動物細胞増殖促進剤及び無血清培地 |
CN1088448A (zh) | 1992-12-25 | 1994-06-29 | 彭德赐 | 西洋参多糖营养液和西洋参多糖胶囊及其制备方法 |
US6083932A (en) * | 1997-04-18 | 2000-07-04 | Cv Technologies Inc. | Pharmaceutical compositions derived from ginseng and methods of treatment using same |
CA2301860C (en) * | 1997-08-28 | 2009-05-26 | Cv Technologies Inc. | Chemical and pharmacological standardization of herbal extracts |
ATE380555T1 (de) | 1999-02-25 | 2007-12-15 | Fx Life Sciences Internat Gmbh | Behandlung von autoimmunkrankheiten mit einem extrakt von amerikanischem ginseng |
US6555527B1 (en) | 1999-08-27 | 2003-04-29 | Korea Atomic Energy Research Institute | Hematopoietic, myeloprotecting, antitumor immune cells generating and radiosensitizing polysaccharide isolated from Panax ginseng |
EP1463944A4 (en) | 2001-12-21 | 2006-05-10 | Eastern Virginia Med School | METHOD OF ANALYZING THE EFFECTS OF MEDICINAL AGENTS |
KR100555652B1 (ko) * | 2002-04-08 | 2006-11-10 | 주식회사 진생사이언스 | 약효가 증강된 파낙스속 식물의 가공 추출물, 그 제조방법및 그를 함유하는 암 및 알러지 질환의 예방 및 치료를위한 조성물 |
WO2003086438A1 (en) * | 2002-04-08 | 2003-10-23 | Ginseng Science Inc. | Extract of processed panax genus plant, the preparation method thereof, and compositions containing the same |
KR100594353B1 (ko) * | 2002-05-28 | 2006-07-03 | 주식회사 엠디바이오알파 | 신규한 인삼잎 및 줄기 다당체, 그 제조방법 및 그를활성성분으로 함유하는 항암제 및 항암보조제 조성물 |
US20050287230A1 (en) | 2004-06-25 | 2005-12-29 | Jeffrey Young | Method of producing ginsenoside 20 (R)-Rh2 and composition of matter thereof |
US8309075B2 (en) * | 2005-11-14 | 2012-11-13 | Nutrileads | Edible product containing ginseng polysaccharides and beneficial bacteria |
US20090047405A1 (en) * | 2007-08-16 | 2009-02-19 | Conopco, Inc., D/B/A Unilever | Food composition with therapeutic agents |
-
2009
- 2009-02-27 MX MX2010009479A patent/MX2010009479A/es active IP Right Grant
- 2009-02-27 ES ES09716101.2T patent/ES2539532T3/es active Active
- 2009-02-27 AU AU2009219793A patent/AU2009219793B2/en not_active Ceased
- 2009-02-27 BR BRPI0908541A patent/BRPI0908541B8/pt active IP Right Grant
- 2009-02-27 JP JP2010548206A patent/JP5879037B2/ja active Active
- 2009-02-27 WO PCT/IB2009/000379 patent/WO2009106975A2/en active Application Filing
- 2009-02-27 PL PL09716101T patent/PL2268295T3/pl unknown
- 2009-02-27 EP EP09716101.2A patent/EP2268295B1/en not_active Not-in-force
- 2009-02-27 SG SG2013015227A patent/SG188833A1/en unknown
- 2009-02-27 CN CN2009801140177A patent/CN102014941B/zh active Active
- 2009-02-27 MY MYPI2010004057A patent/MY158195A/en unknown
- 2009-02-27 NZ NZ587615A patent/NZ587615A/xx not_active IP Right Cessation
- 2009-02-27 KR KR1020107021415A patent/KR101664871B1/ko active IP Right Grant
- 2009-02-27 US US12/919,941 patent/US20110086052A1/en not_active Abandoned
- 2009-02-27 CA CA2716366A patent/CA2716366C/en active Active
-
2013
- 2013-03-18 US US13/846,267 patent/US9050313B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2002508329A (ja) * | 1997-12-12 | 2002-03-19 | シーヴイ テクノロジーズ インコーポレイテッド | 北アメリカ薬用人参分留物の形成方法、それらを含む生成物および免疫賦活剤としての使用方法 |
JP2002017299A (ja) * | 2000-07-10 | 2002-01-22 | Rasheru Seiyaku Kk | 健康食品 |
Non-Patent Citations (3)
Title |
---|
JPN6013019649; Journal of the American Geriatrics Society Vol.52, No.1, 2004, p.13-19 * |
JPN6013019652; Canadian Medical Association Journal Vol.173, No.9, 2005, p.1043-1048 * |
JPN6014010532; Predy, Gerry N. et al: 'Immune modulating effects of daily supplementation of COLD-fX (a proprietary extract of north Americ' Journal of Clinical Biochemistry and Nutrition Vol.39,No.3, 2006, pp.162-167 * |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20210196776A1 (en) * | 2018-05-02 | 2021-07-01 | Amorepacific Corporation | Composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides |
JP2021521868A (ja) * | 2018-05-02 | 2021-08-30 | アモーレパシフィック コーポレーションAmorepacific Corporation | 高麗人参の実多糖体を含むインフルエンザウイルス感染の予防又は抑制用組成物 |
US11642387B2 (en) | 2018-05-02 | 2023-05-09 | Amorepacific Corporation | Composition for preventing or inhibiting influenza virus infection, containing ginseng berry polysaccharides |
JP7273065B2 (ja) | 2018-05-02 | 2023-05-12 | アモーレパシフィック コーポレーション | 高麗人参の実多糖体を含むインフルエンザウイルス感染の予防又は抑制用組成物 |
Also Published As
Publication number | Publication date |
---|---|
CN102014941A (zh) | 2011-04-13 |
JP5879037B2 (ja) | 2016-03-08 |
US9050313B2 (en) | 2015-06-09 |
CN102014941B (zh) | 2013-11-06 |
BRPI0908541B1 (pt) | 2021-05-11 |
MY158195A (en) | 2016-09-15 |
CA2716366A1 (en) | 2009-09-03 |
KR101664871B1 (ko) | 2016-10-11 |
MX2010009479A (es) | 2010-12-07 |
BRPI0908541A2 (pt) | 2019-08-27 |
BRPI0908541B8 (pt) | 2021-05-25 |
WO2009106975A3 (en) | 2009-10-29 |
ES2539532T3 (es) | 2015-07-01 |
AU2009219793A1 (en) | 2009-09-03 |
AU2009219793B2 (en) | 2013-09-26 |
SG188833A1 (en) | 2013-04-30 |
EP2268295B1 (en) | 2015-03-25 |
US20130295205A1 (en) | 2013-11-07 |
EP2268295A2 (en) | 2011-01-05 |
US20110086052A1 (en) | 2011-04-14 |
CA2716366C (en) | 2018-02-27 |
PL2268295T3 (pl) | 2015-08-31 |
KR20100124304A (ko) | 2010-11-26 |
NZ587615A (en) | 2012-10-26 |
WO2009106975A2 (en) | 2009-09-03 |
EP2268295A4 (en) | 2012-03-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP5879037B2 (ja) | 人参抽出物による先天免疫応答および適応免疫応答の活性化 | |
Lee et al. | Effect of dietary curcuma, capsicum, and lentinus, on enhancing local immunity against Eimeria acervulina infection | |
TWI503125B (zh) | 包含以聚肌苷酸-聚胞苷酸為主之佐劑的免疫原組合物 | |
WO2015156339A1 (ja) | 免疫バランス調整剤 | |
US8182846B2 (en) | Plant extracts and uses thereof | |
JP2010502766A (ja) | アジュバントとしてのキチン微粒子 | |
Lin et al. | A polysaccharide purified from Ganoderma lucidum acts as a potent mucosal adjuvant that promotes protective immunity against the lethal challenge with enterovirus A71 | |
Cai et al. | The secretion of sIgA and dendritic cells activation in the intestinal of cyclophosphamide-induced immunosuppressed mice are regulated by Alhagi honey polysaccharides | |
US20090162324A1 (en) | Use of Whole Cell Actinomycetales Bacteria to Treat Stress-Induced Pulmonary Haemorrhage | |
JP6019492B2 (ja) | 乳酸菌および抗原物質を含み、口腔内に投与されることを特徴とする抗アレルギー剤 | |
Bulfon et al. | Protec™ improves innate immune response and specific antibody response against Lactococcus garvieae in rainbow trout (Oncorhynchus mykiss) | |
JP5372547B2 (ja) | 免疫グロブリンa産生促進剤 | |
Chaudhary et al. | A New Vaccine Strategy of Dendritic Cell Presented Kinetoplastid Membrane (KMP-11) as Immunogen for Control against Experimental Visceral Leishmaniasis | |
KR20230105146A (ko) | 장관면역 및 전신면역능 활성을 나타내는 생약 조성물 | |
JP2006257040A (ja) | アレルゲン特異的IgE抗体産生抑制剤、及びアレルゲン特異的IgE抗体産生抑制のために用いられる飲食品 | |
US20220257752A1 (en) | New use of cyclic dinucleotides | |
WO2013081425A1 (ko) | 소자 추출물을 유효성분으로 함유하는 천식의 예방 또는 치료용 조성물 | |
Hassan et al. | Evaluation of Inosine-Acedoben-Dimepranol as an immunomodulator in broiler chicks vaccinated with infectious bronchitis virus vaccine. | |
CN118086212A (zh) | 新冠病毒表位多肽致敏的树突状细胞及其应用 | |
EP1242102A2 (en) | Asthma/allergy therapy that targets t-lymphocytes and/or eosinophils | |
KR20140075065A (ko) | 관중 추출물을 함유하는 면역 활성 증강용 조성물 | |
KR101637472B1 (ko) | 마늘 추출물을 유효 성분으로 포함하는 인플라마좀 매개 염증성 질환 예방 및 치료용 조성물 | |
KR20130062245A (ko) | 소자 추출물을 유효성분으로 함유하는 천식의 예방 또는 치료용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20111115 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20111115 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20121102 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130424 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20130724 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140310 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140521 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20140521 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20141202 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20150326 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A711 Effective date: 20150501 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20150501 |
|
A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20150528 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20150730 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151026 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20151126 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20151210 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20160106 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20160201 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5879037 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |